NovaBridge Biosciences
NASDAQ:NBPBiotechnology
Healthcare
$0.90 -4.78%
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
52W Low $1.46High $6.79
Volume 0.87M
Average 0.90M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$13.48M
FY 2025 · Annual
Net Income
-$6.61M
FY 2025 · Annual
Income Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 88.03M | (10.7M) | 4.49M | 0 | 0 |
| Cost of Revenue | 46.43M | 0 | 0 | 0 | 0 |
| Gross Profit | 41.59M | (10.7M) | 4.49M | 0 | 0 |
| Gross Margin | 47.3% | 100.0% | 100.0% | — | — |
| Research & Development | 190.29M | 155.51M | 114.36M | 158.9M | 8.99M |
| Selling, General & Admin | 899.94M | 199.88M | 63.91M | 216.46M | 4.48M |
| Operating Expenses | 2.11B | 355.38M | 515.65M | 375.36M | 13.48M |
| Depreciation & Amortization | 13.78M | 1.42M | 3.37M | 1.91M | 122.37K |
| EBITDA | (2.06B) | (51.23M) | (344.25M) | (373.45M) | (13.35M) |
| EBITDA Margin | -2337.4% | 478.9% | -7674.2% | — | — |
| Operating Income | (2.07B) | (366.08M) | (511.16M) | (375.36M) | (13.48M) |
| Operating Margin | -2353.1% | 3422.2% | -11395.1% | — | — |
| Interest Income | 21.33M | 4.95M | 7.3M | 54.64M | 1.09M |
| Interest Expense | 0 | 0 | 101.85K | 0 | 0 |
| Other Income / Expenses | (260.73M) | (607.09M) | (954.53M) | 12.63M | 847.61K |
| Income Before Tax | (2.33B) | (973.17M) | (1.47B) | (362.73M) | (12.63M) |
| Pre-Tax Margin | -2649.3% | 9097.4% | -32674.0% | — | — |
| Income Tax Expense | (494.81K) | 710.39K | (1.26B) | 0 | 0 |
| Net Income | (2.33B) | (2.51B) | (1.47B) | (162.26M) | (6.61M) |
| Net Margin | -2648.7% | 23438.9% | -32674.0% | — | — |
| EPS (Basic) | (30.70) | (30.38) | (17.62) | (4.46) | (0.16) |
| EPS (Diluted) | (30.68) | (30.38) | (17.62) | (4.46) | (0.16) |
| 75.93M | 82.52M | 83.19M | 81.19M | 41.64M | |
| 75.96M | 82.52M | 83.23M | 81.19M | 41.64M |
NBP Earnings Waterfall · TTM
NASDAQ:NBP · Revenue to Net Income
Key Ratios
EPS$-0.60
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-39.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$19.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.60, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 5, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 2, 2026 | |
| 6-K | 6-K filing | Oct 28, 2026 | |
| 6-K | 6-K filing | Oct 26, 2026 | |
| 6-K | 6-K filing | Oct 23, 2026 |
How much revenue does NBP generate?
NovaBridge Biosciences (NBP) reported $0.00 of revenue in fiscal 2025.
Is NBP profitable?
NovaBridge Biosciences (NBP) reported -$6.61M of net income.
Continue the stock analysis
Jump to another research area for this company.